Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Why reform needs to start at cancer care

Brian Klepper, PhD
Meds
October 29, 2015
92 Shares
Share
Tweet
Share

Recently, the clinically positive results from the CLEOPATRA oncology trial were released, showing that pertuzumab, when added to docetaxel and trastuzumab as first-line chemotherapy, produces an average survival benefit of 15.7 months in HER2 positive breast cancer patients.

That good news notwithstanding, the authors calculated that Genentech’s price for adding pertuzumab to gain one quality adjusted life year is a breathtaking $713,219. In dry academic language, the authors dropped a bombshell conclusion. “The addition of pertuzumab to a standard regimen … for treatment of metastatic HER2-overexpressing breast cancer is unlikely to provide reasonable value for money spent in the United States compared with other interventions generally deemed cost effective. This analysis highlights the economic challenges of extending life for patients with non-curable disease.

Drugs only consume about a quarter of cancer costs. The other three-quarters are distributed between physicians, outpatient facilities and hospitals, delivering such lucrative returns that hospitals are rushing to get in on the action. As many as one in four U.S. hospitals are building new cancer centers now. Hospitals’ acquisitions of oncology practices have accelerated, in part because they can charge almost twice as much as physician practices for chemotherapies and other cancer drugs.

Change has been simmering in oncology for some time, but now it is coming to a boil. It is clear that cancer professionals — physicians, researchers and society execs — have felt uncomfortably complicit with a paradigm that too often extracts exorbitant sums of money for miniscule clinical benefit. In the past, it has been all but forbidden to consider cost when making clinical decisions. But even in our ossified system, clinicians have been so offended by excessive cost and nominal benefit that they have begun to mobilize.

Last July, 118 leading oncologists from major cancer centers signed an open letter in the Mayo Clinic Proceedings, condemning the harm that excessive cancer drug pricing exerts on patients and families, and urging new cost control regulations. They note, “There is no relief in sight because drug companies keep challenging the market with even higher prices. This raises the question of whether current pricing of cancer drugs is based on reasonable expectation of return on investment or whether it is based on what prices the market can bear.”

In the past, drug manufacturers would no doubt have shrugged, but they’re almost certainly carefully watching this development. Three years ago Memorial Sloan Kettering very publicly refused to carry Zaltrap, a colorectal cancer drug that performs similarly to another medicine, Avastin, but at twice the price. Faced with a public relations disaster, Sanofi immediately caved, halving Zaltrap’s price rather than face the prospect of other cancer centers following suit. Market forces can work.

Cancer’s intensifying rush of new treatments and extreme cost has moved leading oncology organizations to go a step further. They’re developing objective methodologies for valuing clinical treatments. Last June, the American Society of Clinical Oncology published a statement describing a draft “conceptual framework” for assessing the value of cancer therapies based on treatment benefits, toxicities and cost. Frameworks with similar intent are under development by the National Comprehensive Cancer Network, Memorial Sloan Kettering’s Center for Health Policy and Outcomes and others.

With multiple efforts underway to address a common problem, a call for a single national (or global) value framework was inevitable. Daniel Goldstein MD, an Atlanta researcher, wrote, “There is currently a crucial step in the drug development and approval process that is missing — an evaluation of cost and value.” In other words, Dr. Goldstein and his team urged the Food and Drug Administration to develop, refine and adopt a framework that establishes value-based pricing for all oncology drugs seeking approval.

Of course, tools that clarify value promise to be hugely useful in cancer care, where patients and purchasers face questionable treatments and immense costs. But these tools are also desperately needed in the rest of health care. Consider the specialty drug market, where U.S. pricing is rising almost 20 times faster than conventional drugs, generally without being tethered to an identifiable rationale. Most of health care — cardiovascular care, musculoskeletal care, dialysis, imaging, hospital pricing — suffers from rampant excess and can only benefit from credible assessments of value.

Cancer care is a concentrated microcosm of broader health industry practices because it resides at the nexus of aspirational technologies, enormous costs, hope, and death. The cancer community’s pioneering valuation efforts and pushbacks against profiteering are remarkable because they offer sorely-needed context for clinical and financial decision-making, reflecting the imperative that we can’t afford poor cancer solutions much longer. The rest of health care can’t be far behind.

Brian Klepper is a health care analyst and principal, Health Value Direct.  This article originally appeared in the Health Care Blog.

Prev

My patients have shown me that medicine is a universally spoken language

October 29, 2015 Kevin 1
…
Next

Beyond the death count: The psychological casualties of mass violence

October 30, 2015 Kevin 0
…

Tagged as: Oncology/Hematology

Post navigation

< Previous Post
My patients have shown me that medicine is a universally spoken language
Next Post >
Beyond the death count: The psychological casualties of mass violence

More by Brian Klepper, PhD

  • a desk with keyboard and ipad with the kevinmd logo

    The FDA’s epic regulatory failure

    Brian Klepper, PhD
  • a desk with keyboard and ipad with the kevinmd logo

    Will fee for service ever go away?

    Brian Klepper, PhD
  • a desk with keyboard and ipad with the kevinmd logo

    Stop pursuing self-pay patients as a windfall opportunity

    Brian Klepper, PhD

Related Posts

  • Obstruction of medical justice: How health care fails patients with cancer

    Miriam A. Knoll, MD
  • Despite progress in cancer care, cost and equity challenges still must be addressed

    David M. Aboulafia, MD
  • A letter to a cancer patient in palliative care

    Alison Vasa
  • Cancer care costs everyone too much. What can we do about it?

    Andrew Hertler, MD
  • When breast cancer screening guidelines conflict: Some patients face real consequences

    Leda Dederich
  • 4 disturbing trends in health care

    Praveen Suthrum

More in Meds

  • Levamisole is good for your dog, but bad for your cocaine

    Robert Killeen, MD
  • 13.1 million missing Americans since 1980. Where’s the outrage?

    Steve Burgess, MD
  • Ketamine for mental health conditions: What every primary care physician needs to know

    Carlene MacMillan, MD & L. Alison McInnes, MD
  • Learn to be a Narcan hero: a comic tutorial

    Emily Watters, MD
  • The preference for insurance coverage of opioids over non-pharmaceutical options explained

    Amy Baxter, MD
  • A comic reveals the terrifying truth about fentanyl

    Emily Watters, MD
  • Most Popular

  • Past Week

    • Challenging the diagnosis: dehydration or bias?

      Sydney Lou Bonnick, MD | Physician
    • A teenager’s perspective: the pressing need for mental health days in schools

      Ruhi Saldanha | Conditions
    • Air quality alert: Reducing our carbon footprint in health care

      Shreya Aggarwal, MD | Conditions
    • Understanding reproductive rights: complex considerations

      Anonymous | Physician
    • America’s young men are facing a mental health crisis. Can we help them before it’s too late?

      Henna Hundal and Karan Patel | Conditions
    • A doctor’s journey through narcissistic abuse [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Medical gaslighting: a growing challenge in today’s medical landscape

      Tami Burdick | Conditions
    • I want to be a doctor who can provide care for women: What states must I rule out for my medical education?

      Nandini Erodula | Education
    • Balancing opioid medication in chronic pain

      L. Joseph Parker, MD | Conditions
    • Unveiling excessive medical billing and greed

      Amol Saxena, DPM, MPH | Policy
    • The erosion of patient care

      Laura de la Torre, MD | Physician
    • I’m a doctor, and I almost died during childbirth

      Bayo Curry-Winchell, MD | Physician
  • Recent Posts

    • A doctor’s journey through narcissistic abuse [PODCAST]

      The Podcast by KevinMD | Podcast
    • Pioneering space race research: G-forces and human physiology

      Earl Howard Wood, MD, PhD | Conditions
    • How to pick the right mutual funds to reduce your taxes

      Amarish Dave, DO | Finance
    • What is the physician’s role in the food is medicine movement?

      Deb Kennedy, PhD | Conditions
    • America’s young men are facing a mental health crisis. Can we help them before it’s too late?

      Henna Hundal and Karan Patel | Conditions
    • When physicians are disrespected [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • FDA Panel Endorses DFMO for Kids' High-Risk Neuroblastoma in Remission
  • How Bad Will This Respiratory Virus Season Be? CDC Weighs In.
  • Esketamine Tops Quetiapine in Treatment-Resistant Depression
  • Everything (Maybe) You Wanted to Know About Sarilumab for PMR
  • Parkinsonism Case Tied to Welding, Improved With Chelation

Meeting Coverage

  • Use of Recent Diagnostic CT Scans for Palliative RT Planning Reduced Treatment Time
  • Hypofractionated RT for Breast Cancer Post-Mastectomy as Effective as Standard RT
  • SBRT Noninferior to Conventional RT for Intermediate-Risk Prostate Cancer
  • Mixed Bag for Early Metformin in Gestational Diabetes
  • Adding Tirzepatide to Basal Insulin Cuts HbA1c in Poorly Controlled T2D
  • Most Popular

  • Past Week

    • Challenging the diagnosis: dehydration or bias?

      Sydney Lou Bonnick, MD | Physician
    • A teenager’s perspective: the pressing need for mental health days in schools

      Ruhi Saldanha | Conditions
    • Air quality alert: Reducing our carbon footprint in health care

      Shreya Aggarwal, MD | Conditions
    • Understanding reproductive rights: complex considerations

      Anonymous | Physician
    • America’s young men are facing a mental health crisis. Can we help them before it’s too late?

      Henna Hundal and Karan Patel | Conditions
    • A doctor’s journey through narcissistic abuse [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Medical gaslighting: a growing challenge in today’s medical landscape

      Tami Burdick | Conditions
    • I want to be a doctor who can provide care for women: What states must I rule out for my medical education?

      Nandini Erodula | Education
    • Balancing opioid medication in chronic pain

      L. Joseph Parker, MD | Conditions
    • Unveiling excessive medical billing and greed

      Amol Saxena, DPM, MPH | Policy
    • The erosion of patient care

      Laura de la Torre, MD | Physician
    • I’m a doctor, and I almost died during childbirth

      Bayo Curry-Winchell, MD | Physician
  • Recent Posts

    • A doctor’s journey through narcissistic abuse [PODCAST]

      The Podcast by KevinMD | Podcast
    • Pioneering space race research: G-forces and human physiology

      Earl Howard Wood, MD, PhD | Conditions
    • How to pick the right mutual funds to reduce your taxes

      Amarish Dave, DO | Finance
    • What is the physician’s role in the food is medicine movement?

      Deb Kennedy, PhD | Conditions
    • America’s young men are facing a mental health crisis. Can we help them before it’s too late?

      Henna Hundal and Karan Patel | Conditions
    • When physicians are disrespected [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Why reform needs to start at cancer care
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...